Lyra Therapeutics Inc (LYRA NASDAQ) stock market data APIs
$9.1619
0.46(5%)
as of June 27, 2025
Try our APIs with
free plan!
Lyra Therapeutics Inc Financial Data Overview
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Prev. Close
9.1619
Open
9.6234
High
9.9327
Low
8.7125
52 wk Range
3.81-34
Market Cap
12 074 K
Shares Outstanding
1 325 K
Revenue
1 185 K
EPS
-0.13
Beta
0.005
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Lyra Therapeutics Inc data using free add-ons & libraries
Get Lyra Therapeutics Inc Fundamental Data
Lyra Therapeutics Inc Fundamental data includes:
- Net Revenue: 1 185 K
- EBITDA: -44 702 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-28
- EPS/Forecast: -0.1367
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Lyra Therapeutics Inc News
New
Lyra Therapeutics Raises $5 Mln In Direct Offering, Eyes $9.8 Mln Via Warrant Exercises
(RTTNews) - Lyra Therapeutics Inc. (LYRA) announced Friday a registered direct offering of 423,372 shares of common stock (or pre-funded warrants) priced at-the-market under Nasdaq rules, along with a...
Lyra Therapeutics to raise up to $15M via registered direct offering and concurrent private placement, stock falls 22%
Lyra Therapeutics (NASDAQ:LYRA [https://seekingalpha.com/symbol/LYRA]) announced that it will raise capital [https://seekingalpha.com/pr/20150434-lyra-therapeutics-announces-up-to-approximately-15-mil...
Lyra Therapeutics raises $5 million in registered direct offering
WATERTOWN, Mass. - Lyra Therapeutics, Inc. (NASDAQ:LYRA), currently trading at $13.38 with a market capitalization of $17.73 million, has secured approximately $5 million through a registered direct o...
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
WATERTOWN, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-infl...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
